American Cancer Society/Slalom used the Cloud ML Engine on Google Cloud to improve timeliness and accuracy.
To identify novel patterns in digital pathology images, the American Cancer Society partnered with Slalom and used Cloud ML Engine on Google Cloud Platform to improve timeliness and accuracy.
Google Cloud Results
- Identifies patterns in digital images of breast cancer tissues to potentially improve patient outcomes
- Enhances quality and accuracy of image analysis by removing human limitations, fatigue, and bias
- Protects valuable tissue samples by backing up image data to the cloud
- Provides a reliable and scalable platform for future image analysis
12x faster image analysis with ML for improved patient outcomes
Cancer is the second most common cause of death in the United States, accounting for nearly one in four deaths. Among women, breast cancer is the most commonly diagnosed type of cancer and the second leading cause of cancer death in the United States. If detected early, breast cancer is one of the most survivable cancers: the five- and ten-year relative survival rates for women with invasive breast cancer are 90 percent and 83 percent, respectively. However, some molecular subtypes of breast cancer have a poor prognosis and there is limited understanding of these subtypes.
Since 1992, the American Cancer Society has conducted the Cancer Prevention Study-II (CPS-II) Nutrition cohort, a prospective study of more than 188,000 American men and women. CPS-II provides valuable information for researchers to explore how factors such as height, weight, demographic characteristics, personal and family history, use of medicines and vitamins, occupational exposures, dietary habits, alcohol and tobacco use, and reproductive history can affect cancer etiology and prognosis.
The CPS-II Nutrition cohort provides a rich resource for researchers studying cancer. Mia M. Gaudet, PhD, is Scientific Director of Epidemiology Research at the American Cancer Society, and her research is focused on breast cancer. For approximately 1,700 CPS-II participants diagnosed with breast cancer, she was able to obtain medical records and surgical tissue samples, giving her valuable data to help answer pressing questions: What lifestyle, medical, and genetic factors are related to molecular subtypes of breast cancer? Do different features in the breast cancer tissue translate to a better survival rate?